Lynch Regenerative Medicine
FRANKLIN, TN · Biotechnology, Health Care · 13 employees
Lynch Regenerative Medicine, LLC., is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage, and our decades-long commitment to safe and effective regenerative products of the highest quality, to deliver exceptional results for our customers and their patients and thereby redefine
Funding history
- Series series a — $10.0M — Jul 2024
- Series seed — $3.8M — Feb 2024
Recent signals
- Feb 18, 2026: Lynch Regenerative Medicine Appoints Madison Dini as Chief Legal Officer and Chad Lindemann as Chief Marketing Officer
- May 08, 2025: Lynch Regenerative Medicine Appoints Charlie Hee as Chief Scientific Officer
- Nov 20, 2024: Lynch Regenerative Medicine, LLC. Appoints Rob Hubert as Chief Revenue Officer
- Jul 17, 2024: Raised $10.0M in Series series a
- Feb 01, 2024: Raised $3.8M in Series seed
See plans & pricing → Track Lynch Regenerative Medicine’s funding, hiring, and signals — with verified contacts — on Fundz.